DeGrado

Degron Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of a new class of small-molecule medicines known as molecular glue degraders (MGDs). Utilizing its proprietary GlueXplorer platform, the company identifies and optimizes compounds that induce the degradation of previously undruggable or historically intractable disease-causing proteins. Its lead program, DEG6498, is a first-in-class molecular glue degrader targeting Human antigen R (HuR), an RNA-binding protein implicated in cancer and inflammatory diseases. Degron's approach leverages a structurally differentiated compound library and advanced screening systems to expand the reach of targeted protein degradation beyond traditional targets.